Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

Pharmaceutical company Eli Lilly has announced a further €927 million investment at its facility at Raheen in Limerick, creating a further 150 jobs there.

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The ...

Eli Lilly announced more positive results on its weekly insulin, called efsitora alfa, in type 2 diabetes patients. The ...

Eli Lilly will work with RNA-focused Haya Therapeutics to search for new targets to develop drugs for metabolic conditions ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

Christi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job at Gilead's Kite cancer immunotherapy unit. Shares in Lilly were down almost 4% after ...

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple ...

The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech ...

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...